• Je něco špatně v tomto záznamu ?

Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015

J. Blatný, M. Kardos, P. Miljic, E. Bilić, M. Benedik-Dolničar, B. Faganel-Kotnik, D. Konstantinov, Z. Kovalova, P. Ovesná

. 2021 ; 198 (-) : 196-203. [pub] 20201216

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019388

INTRODUCTION: This study analyses real-world data on 144 previously untreated patients (PUPs) with severe Haemophilia A, from seven countries in Central and Eastern Europe (CEE: Bulgaria, Croatia, Czech Republic, Hungary, Latvia, Serbia, and Slovenia), over a period of 11 years. It analyses the risk factors associated with development of inhibitors to factor VIII concentrates. METHODS: Cox proportional hazard models were used to estimate the hazard risk of factors possibly influencing the development of inhibitors. Patients were followed for up to 100 exposure days (EDs). RESULTS: Cumulative inhibitor incidence at the time of 100 EDs was 18.7%, slightly lower than the 25-35% incidence reported in most studies. Of PUPs who developed inhibitors, a majority (56%) developed them within the first 20 EDs and 88% by the 50th ED. FVIII class (recombinant or plasma-derived) did not influence the inhibitors' incidence rate (p = 0.64). We found a significant protective effect of prophylaxis compared to on-demand treatment (p = 0.003). PUPs who had an intensive peak treatment during the first 50 EDs were at significantly higher risk for inhibitor development (HR (95% CI) 5.3 (2.3-12.5), p < 0.001). CONCLUSION: Inhibitors are and will continue to be the most significant complication of haemophilia treatment with factor concentrates. This is particularly true for haemophilia A. In our cohort, we were able to show that the treatment regimen used during first 50EDs influenced significantly the inhibitor risk, but the class of the factor concentrate did not play an important role. Real world data will remain one of the important resources for improving our knowledge of haemophilia.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019388
003      
CZ-PrNML
005      
20210830100940.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.thromres.2020.12.004 $2 doi
035    __
$a (PubMed)33360154
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Blatný, Jan $u Department of Paediatric Haematology, University Hospital and Masaryk University Brno, Czech Republic. Electronic address: jblatny@med.muni.cz
245    10
$a Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015 / $c J. Blatný, M. Kardos, P. Miljic, E. Bilić, M. Benedik-Dolničar, B. Faganel-Kotnik, D. Konstantinov, Z. Kovalova, P. Ovesná
520    9_
$a INTRODUCTION: This study analyses real-world data on 144 previously untreated patients (PUPs) with severe Haemophilia A, from seven countries in Central and Eastern Europe (CEE: Bulgaria, Croatia, Czech Republic, Hungary, Latvia, Serbia, and Slovenia), over a period of 11 years. It analyses the risk factors associated with development of inhibitors to factor VIII concentrates. METHODS: Cox proportional hazard models were used to estimate the hazard risk of factors possibly influencing the development of inhibitors. Patients were followed for up to 100 exposure days (EDs). RESULTS: Cumulative inhibitor incidence at the time of 100 EDs was 18.7%, slightly lower than the 25-35% incidence reported in most studies. Of PUPs who developed inhibitors, a majority (56%) developed them within the first 20 EDs and 88% by the 50th ED. FVIII class (recombinant or plasma-derived) did not influence the inhibitors' incidence rate (p = 0.64). We found a significant protective effect of prophylaxis compared to on-demand treatment (p = 0.003). PUPs who had an intensive peak treatment during the first 50 EDs were at significantly higher risk for inhibitor development (HR (95% CI) 5.3 (2.3-12.5), p < 0.001). CONCLUSION: Inhibitors are and will continue to be the most significant complication of haemophilia treatment with factor concentrates. This is particularly true for haemophilia A. In our cohort, we were able to show that the treatment regimen used during first 50EDs influenced significantly the inhibitor risk, but the class of the factor concentrate did not play an important role. Real world data will remain one of the important resources for improving our knowledge of haemophilia.
650    _2
$a faktor VIII $7 D005169
650    12
$a hemofilie A $x farmakoterapie $7 D006467
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
651    _2
$a východní Evropa $7 D005061
651    _2
$a Maďarsko $7 D006814
651    _2
$a Lotyšsko $7 D007844
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kardos, Mária $u Department of Paediatrics, Mohács Hospital, Mohács, Hungary
700    1_
$a Miljic, Predrag $u Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia
700    1_
$a Bilić, Ernest $u Department of Pediatrics, University Hospital Centre Zagreb, School of Medicine, Zagreb, Croatia
700    1_
$a Benedik-Dolničar, Majda $u Unit for Haematology and Oncology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia
700    1_
$a Faganel-Kotnik, Barbara $u Unit for Haematology and Oncology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia
700    1_
$a Konstantinov, Dobrin $u Pediatric Hematology & Oncology Department, University Hospital "Tsaritsa Johanna-ISUL", Sofia, Bulgaria
700    1_
$a Kovalova, Zhanna $u Department of Hematology and Oncology, Children's Clinical University Hospital, Riga, Latvia
700    1_
$a Ovesná, Petra $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00004518 $t Thrombosis research $x 1879-2472 $g Roč. 198, č. - (2021), s. 196-203
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33360154 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100941 $b ABA008
999    __
$a ok $b bmc $g 1690252 $s 1139834
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 198 $c - $d 196-203 $e 20201216 $i 1879-2472 $m Thrombosis research $n Thromb Res $x MED00004518
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace